Viewing nowCombinationTelminova Tablet 40/5mg
Amlodipine Besylate 6.935mg · Telmisartan 40mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.

MFDS item code 201605786 · Approved 2016.09.30 · Insurance code 649604640
Treatment of essential hypertension
This medication helps effectively control blood pressure in patients with essential hypertension who have difficulty with blood pressure control using telmisartan or amlodipine as monotherapy.
The recommended dose of this medicine is 1 tablet once daily, taken with water, regardless of meals. It is recommended that it be taken at the same time each day, if possible (e.g., in the morning). Before initiating treatment with this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components as described below, switching directly to this medicine may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. For patients taking telmisartan and amlodipine concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience (limited to this medicine 40/5 mg). ○ Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. However, in patients with severe renal impairment, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. Telmisartan is not removed by hemodialysis. ○ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: The usual amlodipine regimen is recommended for elderly patients, but caution should be exercised when increasing the dose. (See section ‘3. Patients requiring careful administration.’) In elderly patients aged 75 years or older, clearance of amlodipine is reduced; therefore, treatment should be initiated at a low dose and the dose increased gradually.
○ Pediatric patients: Administration of this drug is not recommended because its safety and efficacy have not been established in pediatric patients aged 18 years or younger.
This medication can cause severe harm to the fetus and newborn, especially during the second and third trimesters, and should not be taken by pregnant women or those who may become pregnant. It should not be administered to patients with hypersensitivity to any active ingredient or similar components, patients with obstructive biliary disease, severe hepatic impairment, extreme hypotension, cardiogenic shock, unstable heart failure after acute myocardial infarction, among others. Patients with primary aldosteronism or those with aortic and mitral stenosis, hepatic impairment, gastrointestinal disorders, renovascular hypertension, dialysis patients, and the elderly should use this medication with caution, particularly when combined with other drugs affecting the renin-angiotensin-aldosterone system. The most common side effects of this medication include dizziness and peripheral edema, and symptoms of fainting or severe adverse reactions may rarely occur, so immediate consultation with a doctor is necessary if such symptoms appear. Use of this medication during pregnancy can lead to serious side effects such as decreased renal function in the fetus, oligohydramnios, and reduced skull formation, so it should be discontinued immediately upon confirmation of pregnancy. As this medication lowers blood pressure, patients at risk of hypotension should check their fluid and electrolyte balance before taking it, and should receive appropriate treatment if symptoms of hypotension occur. Serum potassium levels may increase, so patients with impaired renal function or heart failure should undergo regular blood tests to monitor potassium levels. For patients with decreased renal function, renal function may worsen while taking this medication, so regular blood tests to monitor renal function are necessary. The calcium channel blocker component of this medication may increase the risk of angina or myocardial infarction in patients with severe coronary artery disease, thus caution is warranted. Breastfeeding women should avoid taking this medication, and caution should be exercised when driving or operating machinery as dizziness or drowsiness may occur. This medication may interact with other drugs, so consultation with a physician or pharmacist is advisable, especially when taken with digoxin, lithium, warfarin, or non-steroidal anti-inflammatory drugs, and regular monitoring may be necessary. In the case of overdose, symptoms such as hypotension, abnormal heart rate, dizziness, and acute renal failure may occur, and prompt medical attention should be sought. The safety and efficacy of this medication in children have not been adequately established, so it is not recommended for patients under 18 years of age. Elderly patients may have more sensitive physical responses, so caution is required while taking this medication and dosage adjustments may be necessary. Store the product out of the reach of children, do not transfer it to another container, and open the packaging just before use.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in a tightly sealed container that blocks light. Store at room temperature between 1 and 30 degrees Celsius and avoid very hot or cold places.
Oval tablets, white or off-white in color
30 tablets/box [10 tablets/blister x 3], 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.935mg · Telmisartan 40mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 40mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
ILDONG Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 6.935mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationTelmisartan 80mg · Amlodipine Besylate 13.87mg
Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.